Co-Authors
This is a "connection" page, showing publications co-authored by SUSAN HILSENBECK and CHANDANDEEP NAGI.
Connection Strength
0.355
-
STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222.
Score: 0.054
-
A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454.
Score: 0.049
-
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021 May 27; 7(1):63.
Score: 0.049
-
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
Score: 0.044
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
Score: 0.041
-
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. Cancer Res. 2019 01 01; 79(1):61-71.
Score: 0.041
-
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.
Score: 0.040
-
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
Score: 0.037